Recruiting

Observational Study

Sponsor:

Duk-Woo Park, MD

Code:

NCT03826264

Conditions

Heart Valve Diseases

Aortic Valve Insufficiency

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Not accepted

Interventions

TAVR

Study Details

Brief summary:

This registry evaluates the long-term outcome of Transcatheter aortic valve replacement (TAVR) in real-world clinical practice.

Conditions

Heart Valve Diseases

Aortic Valve Insufficiency

Study ID

NCT03826264

Start date

Jun 15, 2019

Status verified date

Dec, 2025

Completion date

Dec 31, 2036

Anticipated

Primary completion date

Dec 31, 2035

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • All patients undergoing TAVR
  • Informed consent

Study Design

Enrollment

10000 participants

Anticipated

Interventions and Outcome Measures

Arms

Korea Centers

Seoul, Korea All Patients undergoing TAVR

Stanford University

California, USA All Patients undergoing TAVR

Northwestern University

Evanston, Illinois, USA All Patients undergoing TAVR

Cheng-Hsin Hospital

Taipei, Taiwan All Patients undergoing TAVR

Interventions

TAVR

transcatheter aortic valve replacement (TAVR)

Primary outcome measure

  • Event rate of all cause death [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Do-yoon Kang, MD

kdy1218@gmail.com

Locations

Stanford University

Recruiting

Stanford, California, United States, 94305

Principal Investigator:

Alan Ching Yuenn Yeung, MD

Northwestern Memorial Hospital

Recruiting

Chicago, Illinois, United States, 60611

Principal Investigator:

James D. Flaherty, MD

More Information

Sponsor

Duk-Woo Park, MD

Last update posted

Jan 2, 2026

Last verified

Dec, 2025

Keywords

  • TAVR
  • TAVI
  • real-world

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Duk-Woo Park, MD on 2026-01-02.